Open Eye

A plain-language record of the U.S. government

substantiveApr 14, 2021 · House roll call · passage · Result: Passed

On Motion to Suspend the Rules and Pass — S 164 — Advancing Education on Biosimilars Act

Advancing Education on Biosimilars Act of 2021

In plain language

  • Senate bill in the 117th Congress.
  • Requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological.
  • House passed it on Apr 14, 2021 (substantive).
Official summary (Congressional Research Service)

Advancing Education on Biosimilars Act of 2021 This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.) The FDA may also maintain and operate a website to provide educational materials about biological products.

View this measure on congress.gov

Roll-call breakdown

Yea412

Democrat: 214 · Republican: 198

Nay8

Republican: 8

Present0

Not Voting9

Democrat: 3 · Republican: 6

How each member voted (429)

Yea (412)

Nay (8)

Not Voting (9)

Party labels reflect each member’s most recent affiliation on record.